about
Omega 3 fatty acid for the prevention of cognitive decline and dementiaNeurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's diseaseGrowing up in a Bubble: Using Germ-Free Animals to Assess the Influence of the Gut Microbiota on Brain and BehaviorThe Eye As a Biomarker for Alzheimer's DiseaseAmyloid-precursor-protein-lowering small molecules for disease modifying therapy of Alzheimer's diseaseDrug Repositioning for Alzheimer's Disease Based on Systematic 'omics' Data MiningSR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.Neuropareidolia: diagnostic clues apropos of visual illusions.Analyzing the genes related to Alzheimer's disease via a network and pathway-based approach18F stilbenes and styrylpyridines for PET imaging of A beta plaques in Alzheimer's disease: a miniperspective.Compliance assessment of ambulatory Alzheimer patients to aid therapeutic decisions by healthcare professionals.A tricyclic antidepressant, amoxapine, reduces amyloid-β generation through multiple serotonin receptor 6-mediated targets.Application of a MRI based index to longitudinal atrophy change in Alzheimer disease, mild cognitive impairment and healthy older individuals in the AddNeuroMed cohort.Cerebrospinal fluid PKR level predicts cognitive decline in Alzheimer's disease.A Review of Recent Advances in Neuroprotective Potential of 3-N-Butylphthalide and Its DerivativesPrion protein is decreased in Alzheimer's brain and inversely correlates with BACE1 activity, amyloid-β levels and Braak stagePreclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.The redox basis of epigenetic modifications: from mechanisms to functional consequences.Comparison of nine tractography algorithms for detecting abnormal structural brain networks in Alzheimer's diseaseStructural and mechanistic commonalities of amyloid-β and the prion proteinPredictors of patient self-ratings of quality of life in Alzheimer disease: cross-sectional results from the Canadian Alzheimer's Disease Quality of Life Study.Association of leisure-time physical activity with cognition by apolipoprotein-E genotype in persons aged 60 years and over: the National Health and Nutrition Examination Survey (NHANES-III)Boosting brain connectome classification accuracy in Alzheimer's disease using higher-order singular value decompositionOxidative Stress-Mediated Brain Dehydroepiandrosterone (DHEA) Formation in Alzheimer's Disease DiagnosisAssociation between Antipsychotic Drugs and Mortality in Older Persons with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Integrating network, sequence and functional features using machine learning approaches towards identification of novel Alzheimer genesInduction of mitochondrial changes associated with oxidative stress on very long chain fatty acids (C22:0, C24:0, or C26:0)-treated human neuronal cells (SK-NB-E).Identification of novel acetylcholinesterase inhibitors through e-pharmacophore-based virtual screening and molecular dynamics simulations.Effects and possible mechanisms of action of acacetin on the behavior and eye morphology of Drosophila models of Alzheimer's disease.Classification of brain disease in magnetic resonance images using two-stage local feature fusionCilostazol as an add-on therapy for patients with Alzheimer's disease in Taiwan: a case control study.Human neural stem cells improve cognition and promote synaptic growth in two complementary transgenic models of Alzheimer's disease and neuronal lossA plan to address Alzheimer's diseaseDiagnostic Potential of Pulsed Arterial Spin Labeling in Alzheimer's Disease.First Do No Harm: Euthanasia of Patients with Dementia in Belgium.Can We Talk through a Robot As if Face-to-Face? Long-Term Fieldwork Using Teleoperated Robot for Seniors with Alzheimer's DiseaseAblation of Prion Protein in Wild Type Human Amyloid Precursor Protein (APP) Transgenic Mice Does Not Alter The Proteolysis of APP, Levels of Amyloid-β or Pathologic PhenotypeAlzheimer's disease-associated mutations increase amyloid precursor protein resistance to γ-secretase cleavage and the Aβ42/Aβ40 ratioSpecific Features of Executive Dysfunction in Alzheimer-Type Mild Dementia Based on Computerized Cambridge Neuropsychological Test Automated Battery (CANTAB) Test Results.Cerebral mTOR signal and pro-inflammatory cytokines in Alzheimer's disease rats.
P2860
Q24202649-A69AC8DA-ED7B-4A98-BD8E-6964CBCD5430Q26741247-07740194-2619-46F1-8560-B0A771C6427EQ26766519-8C5BC1B3-E42A-42EB-B4DF-AB2C080DBDA7Q28070142-6D7B3DB2-F186-480B-B7FD-07DC121F59DAQ28537717-E5B3A153-6C1B-456A-BCE6-0D5A55555BB6Q28555197-AF4D8610-034D-45C1-B54D-18901EA6FA8EQ30318977-5B796F37-0F43-4F95-9710-9CF928074814Q33523533-300B7AE0-22BD-4C17-A71C-97CFB3C4CA9DQ33608642-F8F5E7C3-BA3C-4D72-B36C-EFA99B28FF7BQ33637211-C2C5EE22-FBB4-4631-96F0-30DF8FDDE33AQ33652896-24FFC10C-D43A-409B-8B6F-32094DF705FCQ33890363-12C7B036-AB65-47EC-8B1A-7615B456B0C1Q33891581-10666289-472C-4527-9392-3272AAE36924Q34548296-9FC39C16-4573-4E82-B74B-9240F5BF04F9Q34548561-81BBF49D-A765-4374-8F75-B99EE5CCB671Q34663576-2CA40757-870C-4521-B6FA-D2963D78BC6EQ34725521-1E8B5227-9D15-411E-BCC7-974551DFFEBCQ35055739-6C6D15C6-DE2A-4EE2-BC12-99117580EFF1Q35404678-132921CC-8C6A-4EBB-85D4-F0A27AD744D7Q35578753-54671887-6511-4592-93A8-7913D2C16B23Q35704814-7B35E041-9AFC-45A6-BF6A-E768DFFE4774Q35752962-5C5A5A72-A35C-460B-82DE-0941DCE2C7B6Q35884230-8C28C6FD-C26F-458A-8BF0-C9207F1DE2A1Q35972310-F265F097-1180-4E23-8500-B26E87EF8981Q35975139-5F3B36A7-1843-4A47-9D14-2F9B3D4CDD67Q36166587-590874C7-689C-424E-A2E7-D06F4B48A186Q36167749-494828F9-3A4C-427B-8C83-4078515FAE98Q36174613-EF1B1A4D-6576-471F-A373-05E2C782D052Q36245937-5FD5263B-E3E6-4A6B-976B-9C8B7EC03912Q36282942-0FBF504E-DBA8-4934-912C-A1B8C7EC9A73Q36288900-145D9179-AFEB-4852-8C21-838F3FDC8A37Q36490240-4CC9A412-CA60-4886-85B3-1B7AA6021783Q36577854-6B5C2601-7A45-4F4E-86B1-9884E93DD1BCQ36809274-919412C9-CDEE-4121-B968-902ABA6F615DQ36941628-FDDE5112-14B0-4704-AFEF-23D31CA7C7C1Q37104515-5F27075B-921D-4084-8681-F169F797A7E3Q37119331-62F53AD2-C112-4F45-913E-FEFED6BE1BBCQ37195665-F1453398-007A-4515-AF60-BFD64365A751Q37337804-342CC4F6-D318-43CC-949A-26F2A0414FA9Q37585461-3E9C9AF2-8C27-4265-A8AE-156BCA7114C0
P2860
description
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
BMJ 2009; 338 article by A. Burns and S. Iliffe
@en
article scientifique (publié 2009/02/05)
@fr
articolo scientifico (pubblicato il 2009/02/05)
@it
artigo científico (publicado na 2009/02/05)
@pt
artikull shkencor
@sq
artículo científico
@es
artículu científicu espublizáu en 2009
@ast
vedecký článok (publikovaný 2009/02/05)
@sk
name
Alzheimer's disease
@ast
Alzheimer's disease
@en
Alzheimer's disease
@en-gb
Alzheimer's disease
@nl
type
label
Alzheimer's disease
@ast
Alzheimer's disease
@en
Alzheimer's disease
@en-gb
Alzheimer's disease
@nl
prefLabel
Alzheimer's disease
@ast
Alzheimer's disease
@en
Alzheimer's disease
@en-gb
Alzheimer's disease
@nl
P3181
P356
P1433
P1476
Alzheimer's disease
@en
P304
P3181
P356
10.1136/BMJ.B158
P407
P433
P577
2009-02-05T00:00:00Z